Abstract
Osteosarcoma (OS) is a type of bone malignancy with a high rate of treatment failure. To date, few evident biomarkers for the prognostic significance of OS have been established. Oncomine was used to integrate RNA and DNA-seq data from the Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and the published literature. The correlation of the gene Trophinin (TRO) and different types of cancers was generated using the Cancer Cell Line Encyclopedia (CCLE) online tool. Prognostic values of featured Melanoma Antigen Gene (MAGE) members were further assessed by establishing the overall survival using the Kaplan-Meier plotter. Moreover, the online tool, Database for Annotation, Visualization and Integrated Discovery version (DAVID), was used to understand the biological meaning list of the genes. MAGEB10, MAGED2, TRO, MAGEH1, MAGEB18, MAGEB6, MAGEB4, MAGEB1, MAGED4B, MAGED1, MAGEB2, and MAGEB3 were significantly overexpressed in sarcoma. TRO was further demonstrated to be distinctively upregulated in osteosarcoma cell lines and associated with shorter overall survival. TRO may play an important role in the development of OS and may be a promising potential biomarker and prognostic factor.
Highlights
Osteosarcoma (OS) is the most common bone malignancy in young people, with over 50% of cases occurring in the first two decades of life [1]
Curative treatment of OS remains challenging with subsequent poor prognosis and shortened life expectancy [3]
The expression information of the Melanoma Antigen Gene (MAGE) family in sarcoma and coexpressed genes of the MAGE family were retrieved from Oncomine with the default setting of fold change > 2 and P value < 0.01
Summary
Osteosarcoma (OS) is the most common bone malignancy in young people, with over 50% of cases occurring in the first two decades of life [1]. Tremendous progress has been achieved in the past few decades in the field of OS therapy development including advances in surgical and diagnostic strategies and the use of combined chemotherapy [2]. Despite this progress, curative treatment of OS remains challenging with subsequent poor prognosis and shortened life expectancy [3]. Diagnosis and treatment of OS, with nonmetastatic OS, is crucial for improving the prognosis of OS patients [4]. A better understanding of the molecular and cellular biology and an identification of effective biomarkers involved in tumor initiation and progression are crucial for optimizing diagnosis and treatment of OS
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
